AMI Pitch Deck Teardown: Advanced Medical Isotope Analysis

Introduction and Corporate Status

The Advanced Medical Isotope Corporation (AMI) investor presentation, dated August 1, 2017, introduces a company positioned at the intersection of biotechnology and medical devices. The cover slide (Slide 1) establishes the company's leadership under Dr. Michael Korenko and notes its status as a publicly traded entity on the OTC market under the ticker ADMD. The visual metaphor of a syringe injecting a localized tumor immediately communicates the company's focus on targeted, injectable cancer therapy.

Slide 3: The Strategic Overview

Slide 3 serves as the executive summary. It defines brachytherapy as the treatment of cancer through radioactive implants placed directly into or next to the treatment area. The core value proposition is clearly stated: AMI is pursuing a "device" regulatory path, which typically offers a shorter and less expensive route to market than traditional drug development, while aiming for the high-margin economics associated with pharmaceuticals. The slide also introduces the dual-track strategy of generating near-term revenue from veterinary clinics and international licensing while simultaneously working toward FDA approval for human applications.

Slide 5: RadioGel Technology Platform

This slide provides the technical specifications of the flagship product, RadioGel. It is described as a "next-generation radiopharmaceutical therapeutic device." The technology relies on two components: a hydrogel that remains liquid at room temperature for easy injection but solidifies at body temperature to lock particles in place, and Yttrium-90 phosphate particles. The choice of Yttrium-90 is strategic; as a high-energy beta emitter with a 2.7-day half-life, it delivers a potent dose that dissipates quickly (95% gone after 10 days), minimizing long-term radiation exposure for the patient and surrounding tissue.

Slide 7: The Veterinary Market Entry

Slide 7 outlines a three-step go-to-market strategy for the veterinary sector. The process begins with obtaining approval to test, followed by demonstrating therapies at leading research universities to build clinical credibility, and finally commencing sales to private clinics. This sequence is a standard "low-hanging fruit" strategy in medical tech, where the veterinary market serves as both a revenue source and a real-world proof of concept for human applications.

Slide 9: Veterinary Market Opportunity

The financial justification for the veterinary focus is detailed on Slide 9. Citing a population of 78 million dogs and 86 million cats in the U.S., the slide notes that cancer is the leading cause of death for 50% of dogs over age 10. The revenue model is straightforward: treating 10% of these cancers at a $5,000 price point results in a $40M annual revenue opportunity. Crucially, the slide sets a near-term milestone, stating that revenue streams could begin by January 2018.

Slide 11: Human Skin Cancer Projections

Moving to human applications, Slide 11 focuses on Basal Cell and Squamous Cell carcinomas. The market size is substantial, with 5.4 million cases annually in the U.S. The company applies a similar 10% market penetration assumption as the veterinary slide, which, at a $5,000 price point, yields a projected $1.5 billion in annual revenue. This slide bridges the gap between the smaller veterinary "starter" market and the massive human clinical opportunity.

Slide 13: Medical Sector Growth Strategy

Slide 13 illustrates the roadmap for human clinical indications. The company plans to move through "quantum growth steps" by expanding the use of RadioGel from skin cancer to lymph nodes, and eventually to complex internal organs like the liver and pancreas. This phased approach suggests a strategy of starting with the most accessible (topical/surface) tumors before moving to deeper, more complex internal oncology challenges.

Slide 15: Intellectual Property Protection

For a medical device company, IP is the primary defensive moat. Slide 15 lists the company's assets: eight patents sublicensed from Battelle, trademark protection in 17 countries, and proprietary knowledge regarding production procedures and test data. The mention of a retained IP attorney signals to investors that the company is actively defending and expanding its legal protections.

Slide 17: Medical and Scientific Advisory Boards

Slide 17 focuses on human capital and institutional credibility. By showcasing chairs for Medical, Scientific, and Veterinary advisory boards—including MDs and DVMs with impressive credentials (FACR, FNAP, FASTRO)—AMI attempts to validate its technology through the endorsement of industry experts. This is a critical slide for de-risking the technical claims made earlier in the deck.

Slide 19: Investment Highlights

The final slide in this selection summarizes the pitch. It reiterates the timeline for revenue (January 2018), the strength of the leadership and partnerships, and the strategic goal of uplisting to a senior exchange like the NASDAQ. It reinforces the "drug economics with device pathway" narrative, which is the central pillar of the company's financial appeal.

What Works in This Deck

Clear Technical Differentiation: The explanation of the hydrogel's phase-change properties (liquid to solid) and the specific benefits of Yttrium-90 (short half-life, localized dose) is clear and compelling. It explains how the product works without getting bogged down in impenetrable jargon.

Dual-Market De-risking: The decision to lead with the veterinary market is a strong strategic move. It shows investors a path to cash flow that doesn't rely solely on the multi-year, high-risk FDA human trial process. This "revenue-first" approach is often more attractive to mid-stage investors than a pure-play clinical trial bet.

Regulatory Arbitrage: Positioning the product as a "device" while claiming "drug economics" is a classic medical fundraising tactic. If the company can successfully maintain this classification, it significantly reduces the capital requirements and time-to-market compared to a New Drug Application (NDA).

What Is Missing from This Deck

Competitive Landscape: The deck completely omits a competitor analysis. There is no mention of existing brachytherapy providers, traditional radiation therapy, or emerging immunotherapy treatments that might compete for the same patient pool. Investors need to know why RadioGel is better than the current standard of care.

Unit Economics and Margins: While the deck mentions a $5,000 price point, it does not disclose the Cost of Goods Sold (COGS). Without knowing the manufacturing cost of the isotopes and the hydrogel, it is impossible to verify if the "drug-like economics" claim holds water.

Detailed Use of Proceeds: The deck lacks a specific "Ask" slide in this selection. It does not state how much capital is being raised or exactly how those funds will be allocated between veterinary commercialization and human clinical trials.

Clinical Data: While the deck mentions "all test data" as proprietary IP, it does not show any actual results from animal or human studies. Even preliminary data or case studies from the "leading research universities" mentioned would significantly strengthen the pitch.

What a Founder Should Copy

The Sequential Growth Visual: Slide 13 is an excellent way to show a long-term vision. By starting with a simpler indication (skin cancer) and moving to complex ones (liver/pancreas), the founder demonstrates a logical, risk-adjusted expansion plan.

Market Sizing by Specific Indication: Rather than just citing a "$100 billion cancer market," AMI breaks it down by specific case counts and realistic penetration rates (10%). This makes the $1.5 billion revenue projection feel calculated rather than imagined.

Advisory Board Structure: Segmenting the advisory board into Medical, Scientific, and Veterinary categories shows that the company understands the distinct hurdles in each of those domains and has recruited specific expertise to address them.